Protara Therapeutics, Inc. SEC filings TARA
Protara Therapeutics, Inc. has 809 filings in SEC EDGAR's recent list, going back to Apr 14, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 11, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2026 | Jun 12, 2026 |
| 424B5 | Prospectus supplement | May 28, 2026 | — |
| EFFECT | Filing | May 22, 2026 | — |
| CORRESP | Letter to the SEC | May 20, 2026 | — |
| UPLOAD | Letter from the SEC | May 19, 2026 | — |
| S-3 | Shelf registration | May 14, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 12, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 30, 2026 | Mar 30, 2026 |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2026 | Mar 10, 2026 |
| 424B7 | Prospectus supplement | Mar 6, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 24, 2026 | Feb 23, 2026 |
| 424B7 | Prospectus supplement | Feb 2, 2026 | — |
| 8-K |
Current report
Other events
|
Dec 15, 2025 | Dec 15, 2025 |
| 424B7 | Prospectus supplement | Dec 9, 2025 | — |
| 8-K |
Current report
Material agreement
|
Dec 8, 2025 | Dec 4, 2025 |
| 424B5 | Prospectus supplement | Dec 5, 2025 | — |
| 424B5 | Prospectus supplement | Dec 4, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 3, 2025 | Dec 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 19, 2025 | Nov 19, 2025 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| S-8 | Employee stock plan registration | Aug 11, 2025 | — |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 11, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 424B7 | Prospectus supplement | Apr 28, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 28, 2025 | Apr 26, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 11, 2025 |
| S-8 | Employee stock plan registration | Mar 5, 2025 | — |
| 10-K | Annual report | Mar 5, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2025 | Mar 5, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 11, 2024 | Dec 9, 2024 |
| 424B5 | Prospectus supplement | Dec 11, 2024 | — |
| 424B5 | Prospectus supplement | Dec 9, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 5, 2024 | Dec 5, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| S-8 | Employee stock plan registration | Aug 6, 2024 | — |
| 10-Q | Quarterly report | Aug 6, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2024 | Jun 7, 2024 |
| EFFECT | Filing | May 9, 2024 | — |
| 424B3 | Prospectus | May 9, 2024 | — |
| CORRESP | Letter to the SEC | May 7, 2024 | — |
| UPLOAD | Letter from the SEC | May 7, 2024 | — |
| S-3 | Shelf registration | May 2, 2024 | — |
| 10-Q | Quarterly report | May 2, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 2, 2024 | May 2, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Apr 5, 2024 | Apr 5, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 18, 2024 | Mar 18, 2024 |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| 10-K | Annual report | Mar 13, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2024 | Mar 13, 2024 |
| EFFECT | Filing | Nov 14, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| S-3 | Shelf registration | Nov 3, 2023 | — |
| 10-Q | Quarterly report | Nov 3, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2023 | Nov 3, 2023 |
| 10-Q | Quarterly report | Aug 3, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2023 | Jun 7, 2023 |
| 10-Q | Quarterly report | May 4, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 2, 2023 | May 2, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 28, 2023 | Apr 28, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| ARS | Annual report to shareholders | Apr 26, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 26, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 10-K | Annual report | Mar 8, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 30, 2023 | Jan 30, 2023 |
| 8-K |
Current report
Other events
|
Jan 5, 2023 | Jan 5, 2023 |
| 10-Q | Quarterly report | Nov 3, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 10-Q | Quarterly report | Aug 9, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 18, 2022 | Jul 16, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 21, 2022 | Jun 20, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 8, 2022 |
| 10-Q | Quarterly report | May 5, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 5, 2022 | May 5, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| S-8 | Employee stock plan registration | Mar 9, 2022 | — |
| 10-K | Annual report | Mar 9, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2022 | Mar 9, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 10, 2022 | Jan 10, 2022 |
| 10-Q | Quarterly report | Nov 4, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2021 | Nov 4, 2021 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 18, 2021 | Oct 15, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 12, 2021 | Oct 12, 2021 |
| 10-Q | Quarterly report | Aug 5, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2021 | Aug 5, 2021 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Regulation FD disclosure
|
Jun 10, 2021 | Jun 9, 2021 |
| 10-Q | Quarterly report | May 6, 2021 | Mar 31, 2021 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 9, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 23, 2021 | Apr 23, 2021 |
| 8-K |
Current report
Officer or director change, Other events
|
Apr 19, 2021 | Apr 19, 2021 |
| SEC STAFF LETTER | Filing | Mar 23, 2021 | — |
| 8-K |
Current report
Auditor change
|
Mar 17, 2021 | Mar 12, 2021 |
| S-8 | Employee stock plan registration | Mar 11, 2021 | — |
| 10-K | Annual report | Mar 11, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Other events
|
Mar 3, 2021 | Mar 3, 2021 |
| SEC STAFF LETTER | Filing | Feb 23, 2021 | — |
| 8-K |
Current report
Other events
|
Feb 11, 2021 | Feb 11, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 2, 2021 | Jan 29, 2021 |
| EFFECT | Filing | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2020 | — |
| CORRESP | Letter to the SEC | Dec 15, 2020 | — |
| S-3 | Shelf registration | Dec 9, 2020 | — |
| 8-K |
Current report
Material agreement
|
Dec 8, 2020 | Dec 7, 2020 |
| 8-K |
Current report
Officer or director change
|
Dec 7, 2020 | Dec 1, 2020 |
| 8-K |
Current report
Other events
|
Nov 17, 2020 | Nov 12, 2020 |
| 10-Q | Quarterly report | Nov 12, 2020 | Sep 30, 2020 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Oct 8, 2020 | Jun 9, 2020 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change, Other events
|
Sep 23, 2020 | Sep 21, 2020 |
| 424B5 | Prospectus supplement | Sep 23, 2020 | — |
| 424B5 | Prospectus supplement | Sep 23, 2020 | — |
| S-3MEF | Registration statement | Sep 22, 2020 | — |
| 424B5 | Prospectus supplement | Sep 21, 2020 | — |
| 424B5 | Prospectus supplement | Sep 21, 2020 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2020 | Sep 8, 2020 |
| 10-Q | Quarterly report | Jul 31, 2020 | Jun 30, 2020 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 24, 2020 | Jul 20, 2020 |
| 8-K |
Current report
Material agreement
|
Jul 16, 2020 | Jul 14, 2020 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2020 | Jun 9, 2020 |
| EFFECT | Filing | May 26, 2020 | — |
| CORRESP | Letter to the SEC | May 21, 2020 | — |
| UPLOAD | Letter from the SEC | May 21, 2020 | — |
| S-3 | Shelf registration | May 14, 2020 | — |
| 10-Q | Quarterly report | May 13, 2020 | Mar 31, 2020 |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 9, 2020 |
| S-8 | Employee stock plan registration | Mar 31, 2020 | — |
| 8-K |
Current report
Other events
|
Mar 30, 2020 | Mar 26, 2020 |
| 8-K |
Current report
Auditor change
|
Mar 23, 2020 | Mar 18, 2020 |
| 8-K/A | Amended current report | Mar 20, 2020 | Jan 6, 2020 |
| 10-K | Annual report | Mar 20, 2020 | Dec 31, 2019 |
| SEC STAFF LETTER | Filing | Mar 2, 2020 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 11, 2020 | Feb 6, 2020 |
| 424B3 | Prospectus | Feb 11, 2020 | — |
| EFFECT | Filing | Feb 10, 2020 | — |
| CORRESP | Letter to the SEC | Feb 6, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2020 | — |
| SEC STAFF LETTER | Filing | Jan 31, 2020 | — |
| S-3 | Shelf registration | Jan 30, 2020 | — |
| S-8 | Employee stock plan registration | Jan 15, 2020 | — |
| 8-K |
Current report
Acquisition or sale of assets, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jan 10, 2020 | Jan 6, 2020 |
| 8-K |
Current report
Other events
|
Dec 31, 2019 | Dec 31, 2019 |
| 425 | Form 8-k | Dec 31, 2019 | — |
| 8-K |
Current report
Officer or director change
|
Dec 23, 2019 | Dec 20, 2019 |
| RW | Filing | Dec 20, 2019 | — |
| EFFECT | Filing | Dec 19, 2019 | — |
| 424B3 | Prospectus | Dec 19, 2019 | — |
| S-4/A | Filing | Dec 18, 2019 | — |
| CORRESP | Letter to the SEC | Dec 18, 2019 | — |
| S-4/A | Filing | Dec 17, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Dec 13, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2019 | — |
| S-4/A | Filing | Dec 5, 2019 | — |
| CORRESP | Letter to the SEC | Dec 4, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2019 | — |
| 8-K |
Current report
Other events
|
Nov 21, 2019 | Nov 15, 2019 |
| 425 | Form 8-k | Nov 21, 2019 | — |
| S-4 | Registration for a merger or exchange | Nov 7, 2019 | — |
| 10-Q | Quarterly report | Oct 31, 2019 | Sep 30, 2019 |
| 8-K |
Current report
Results of operations
|
Oct 31, 2019 | Oct 31, 2019 |
| 8-K |
Current report
Listing notice
|
Oct 10, 2019 | Oct 7, 2019 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2019 | Sep 30, 2019 |
| 8-K |
Current report
Other events
|
Sep 24, 2019 | Sep 24, 2019 |
| 425 | 8-k | Sep 24, 2019 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Sep 24, 2019 | Sep 22, 2019 |
| 425 | 8-k | Sep 24, 2019 | — |
| 8-K |
Current report
Other events
|
Sep 23, 2019 | Sep 23, 2019 |
| 425 | 8-k | Sep 23, 2019 | — |
| 8-K |
Current report
Listing notice
|
Aug 15, 2019 | Aug 12, 2019 |
| 10-Q | Quarterly report | Aug 7, 2019 | Jun 30, 2019 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.